References
- Christian M S, Brent R L, Calda P. Embryo-fetal toxicity signals for 17-alpha-hydroxyprogesterone caproate in high risk pregnancies: a review of the non-clinical literature for embryo-fetal toxicity with progestins. J Maternal Fetal Neonatal Med 2007; 20: 89–112
- Seegmiller R E, Nelson G W, Johnson C K. Evaluation of the teratogenic potential of delalutin (17alpha-hydroxyprogesterone caproate) in mice. Teratology 1983; 28: 201–208
- Hendrickx A G, Korte R, Leuschner F, Neumann B W, Poggel A, Binkerd P, Prahalada S, Gunzel P. Embriotoxicity of sex steroidal hormones in nonhuman primates. II. Hydroxyprogesterone caproate, estradiol valerate. Teratology 1987; 35: 129
- R E Behrman, Butler, A S. Preterm Birth: Causes, Consequences, and Prevention. Washington, D.C., The National Academies Press. 2006
- Review by the Division of Reproduction and Urologic Products, Food and Drug Administration. August 2, 2006, Available: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4227B1-02-01-FDA-Background.pdf (accessed 30 May 2008)
- Summary minutes for the Advisory Committees for Reproductive Health Drugs. August 29, 2006, Available: http://www.fda.gov/ohrms/dockets/ac/06/minutes/2006-4227M1.pdf (accessed 30 May 2008)
- Fonseca E B, Bittar R E, Carvalho H B, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003; 188: 419–424
- Sexton D J, O'Reilly M W, Friel A M, Morrison J J. Functional effects of 17alpha-hydroxyprogesterone caproate on human myometrial contractility in vitro. Reprod Biol Endocrinol 2004; 2: 80
- Csapo A. The “see-saw” theory of parturition. CIBA Foundation Syposium 1977; 47: 159–210
- Ruddock N, Shi S, Jain S, Moore G, Hankins G, Romero R, Garfield R. Progesterone (P4), but not 17 alpha hydroxyprogesterone caproate (17P) inhibits human myometrial contractions. Am J Obstet Gynecol 2007; 197: 6
- Crinone package insert, http://www.crinoneusa.com/professionals/Prescribing_Information.pdf, revised 2006
- O'Brien J M, Adair C D, Lewis D F, Hall D R, DeFranco E A, Fusey S, Soma-Pillay P, Porter K, How H, Schackis R, et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2007; 30: 687–696, http://www3.interscience.wiley.com/journal/99020267/home (free download)
- Keirse M JNC. Progestogen administration in pregnancy may prevent preterm delivery. Br J Obstet Gynecol 1990; 97: 149–154
- Meis P J, Klebanoff M, Thom E, Dombrowski M P, Sibai B, Moawad A H, Spong C Y, Hauth J C, Menachem M, Varner M W, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. New Engl J Med 2003; 348: 2379–2385
- Rebarber A, Ferrara L A, Hanley M L, Istwan N B, Rhea D J, Stanziano G J, Saltzman D H. Increased recurrence of preterm delivery with early cessation of 17-alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol 2007; 196: 224
- Rebarber A, Istwan N B, Russo-Stieglitz K, Cleary-Goldman J, Rhea D J, Stanziano G J, Saltzman D H. Increased incidence of gestational diabetes in women receiving prophylactic 17alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery. Diabetes Care 2007; 30: 2277–2280
- Dodd J M, Flenady V, Cincotta R, Crowther C A. The cochrane database of systematic reviews. 2006, (1) Art. No.: CD004947. DOI: 10.1002/14651858.CD004947.pub2. www.cochrane.org/reviews/en/ab004947.html (accessed 30 May 2008)
- Wesley B. Meeting of the advisory committee for reproductive health drugs. August 29, 2006, Available: http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4227S1-02-03-FDA_Wesley.ppt (slide #9, accessed 30 May 2008)
- Review by the Division of Reproduction and Urologic Products, Food and Drug Administration. August 2, 2006, Available: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4227B1-02-01-FDA-Background.pdf (page 27-28, accessed 30 May 2008)
- Brancazio L R, Murtha A P, Heine R P. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003; 349: 1087
- Review by the Division of Reproduction and Urologic Products, Food and Drug Administration. August 2, 2006, Available: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4227B1-02-01-FDA-Background.pdf (page 41-42, accessed 30 May 2008)